Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells

Pharmaceutical Research

Volumn 15, Issue 10, 1998, Pages 1540-1545

  Li, Song ^a   Deshmukh, Hemant M ^a,b   Huang, Leaf ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Antisense oligodeoxynucleotide; Drug targeting; Folate binding protein; Ovarian carcinoma

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; FOLATE BINDING PROTEIN; FOLIC ACID; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; PROTEIN C FOS; VITAMIN RECEPTOR;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DERIVATIZATION; DRUG CONJUGATION; DRUG EXTRAVASATION; DRUG TARGETING; DRUG UPTAKE; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE C FOS; OVARY CANCER; PRIORITY JOURNAL;

ANIMALS; CARRIER PROTEINS; CHO CELLS; CRICETINAE; DOWN-REGULATION; FEMALE; FOLIC ACID; GENES, FOS; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 0031683544     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011946915209     Document Type: Article

References (27)

1. J. S. Cohen. Antisense oligonucleotides as antiviral agents. Antiviral Res. 16:121-133 (1991).
2. S. T. Crooke. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol. 32:329-376 (1992).
3. C. A. Stein and Y. C. Cheng. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 261:1004-1011 (1993).
4. L. Neckers, L. Whitesell, A. Rosolen, and D. A. Geselowitz. Antisense inhibition of oncogene expression. Crit. Rev. Oncogen. 3:175-231 (1992).
5. C. Cazenave, P. Frank, and W. Busen. Characterization of ribonuclease H activities present in two cell-free protein synthesizing systems, the wheat germ extract and the rabbit reticulocyte lysate. Biochimie 75:113-122 (1993).
6. L. A. Yakubov, H. A. Deeva, V. F. Zarytova, E. M. Ivanova, A. S. Ryte, L. V. Yurchenko, and V. V. Vlassov. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA 86:6454-6458 (1989).
7. S. Akhtar, S. Basu, E. Wickstrom, and R. L. Juliano. Inetractions of antisense DNA oligonucleotide analogs with phopholipid membranes (liposomes). Nucleic Acids Res. 19:5551-5559 (1991).
8. S. L. Loke, C. A. Stein, X. H. Zhang, K. Mori, M. Nakanishi, C. Subasinghe, J. S. Cohen, and L. M. Neckers. Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA 86:3474-3478 (1989).
9. S. Wang, R. J. Lee, G. Cauchon, D. G. Gorenstein, and P. S. Low. Delivery of antisense oligodeoxyribonucleotides against human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA 92:3318-3322 (1995).
10. C. F. Bennett, M. Y. Chaing, H. Chan, J. E. E. Shoemaker, and C. K. Mirabelli. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1023-1033 (1992).
11. F. Cumin, F. Asselbergs, M. Lartigot, and E. Felder. Modulation of human protein gene expression by antisense oligonucleotides in transfected CHO cells. Eur. J. Biochem. 212:347-354 (1993).
12. G. Y. Wu and C. H. Wu. Specific inhibition of hepatitis B viral gene expression by targeted antisense oligonucleotides. J. Biol. Chem. 267:12436-12439 (1992).
13. G. Citro, C. Szczylik, G. Zupi, and B. Calabretta. Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br. J. Cancer 69:463-467 (1994).
14. A. L. Klibanov and L. Huang. Long-circulating liposomes: development and perspectives. J. Liposome Res. 2:321-334 (1992).
15. D. C. Litzinger, J. M. Brown, I. Wala, S. A. Kaufman, G. Y. Van, C. L. Farrell, and D. Collins. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta 1281:139-149 (1996).
16. R. Plourde and G. Y. Wu. Targeted therapy for viral hepatitis. Adv. Drug Deliver Rev. 17:311-315 (1995).
17. 2-mitomycin C conjugate with improved antitumor activity. Bioconjugate Chem. 1:245-250 (1990).
18. K. J. Scanlon, L. Jiao, T. Funato, W. Wang, J. J. Rossi, and M. Kashani-Sabet. Ribozyme-mediated clevage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA 88:10591-10595 (1991).
19. M. A. Piatyszek, A. Jarmolowski, and J. Augustyniak. IodoGen-mediated radioiodination of nucleic acids. Anal. Biochem. 172:356-359 (1988).
20. M. B. Hansen, S. E. Nielson, and K. Berg. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killing. J. Immunol. Methods 119:203-210 (1989).
21. M. Nesterova and Y. S. Chochung. A single-injection protein-kinase A-directed antisense treatment to inhibit tumor growth. Nature Med. 1:528-533 (1995).
22. B. A. Kamen, M. T. Wang, A. J. Streckfuss, X. Peryea, and R. G. W. Anderson. Delivery of folates to the cytoplasm of MA 104 cells is mediated by a surface membrane receptor that recycles. J. Biol. Chem. 263:13602-13609 (1988).
23. M. A. Kane, P. C. Elwood, R. M. Portillo, A. C. Antony, and J. F. Kolhouse. The interrelationship of the soluble and membrane-associated folate-binding proteins in human KB cells. J. Biol. Chem. 261:15625-15631 (1986).
24. I. G. Campbell, T. A. Jones, W. D. Foulkes, and J. Trowsdale. Folate-binding protein is a marker for ovarian cancer. Cancer Res. 51:5329-5338 (1991).
25. C. P. Leamon and P. S. Low. Cytotoxicity of momordin-folate conjugates in cultured human cells. J. Biol. Chem. 267:24966-24971 (1992).
26. R. J. Lee and P. S. Low. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233:134-144 (1995).
27. M. E. Greenberg and B. B. Ziff. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature 311:433-438 (1984).